About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:6192375
Allelic
Composition
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
Genetic
Background
involves: C57BL/6J * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Kdm6atm1Cdcn mutation (0 available); any Kdm6a mutation (40 available)
Tg(CAG-cre/Esr1*)5Amc mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• some tamoxifen-treated mice die between 6 and 20 months of age

neoplasm
• tamoxifen treated mice have hypersegmented neutrophils, immature cells with myelomonocytic features, nucleated red blood cells, biolobed granulocytes, pseudo-Pelger-Huet cells, and megaplatelets, indicating the presence of myelodysplasia
• 7 of 11 mice exhibit myeloproliferative/myelodysplastic neoplasm within 10 months of tamoxifen treatment similar to human chronic myelomonocytic leukemia

hematopoietic system
• mice develop splenomegaly 10 months after tamoxifen injection
• in tamoxifen treated mice
• increase in number of granulocyte-macrophage progenitor (GMP) cells in the bone marrow of tamoxifen treated mice
• the number of burst forming unit-erythroid colonies decreases from 14 to 40 weeks of age in tamoxifen treated mice
• decrease in number of red blood cells in tamoxifen treated mice
• in tamoxifen treated mice
• expansion or infiltration of monocytes and granulocytes in the spleen, bone marrow, and liver of tamoxifen treated mice
• tamoxifen treated mice exhibit expansion of CD11b+Gr1+ neutrophils in spleen
• however, B-cell and T-cell numbers are normal in tamoxifen treated mice
• decrease in number of platelets in tamoxifen treated mice
• expansion or infiltration of monocytes and granulocytes in the spleen, bone marrow, and liver of tamoxifen treated mice
• tamoxifen treated mice exhibit expansion of CD11b+ myeloid cells in spleen
• increase in number of myeloid cells in peripheral blood of tamoxifen treated mice
• an increase in the number and proportion of hematopoietic stem cells (HSCs), including long-term HSCs and short-term HSCs in the bone marrow of tamoxifen treated mice
• however, the number of bone marrow cells is normal
• decrease in number of megakaryocyte-erythroid progenitor (MEP) cells in the bone marrow of tamoxifen treated mice
• increase in serial replating capacity of the bone marrow, LSK (Lin-cKit+Sca1+) and GMP cells from tamoxifen treated mice, indicating an increase in the self-renewal potential of HSCs and progenitor cells
• in vitro assays suggest a differentiation bias of bone marrow and LSK cells toward the myeloid lineage, with an increase in the number of granulocyte-macrophage and granulocyte colonies and decrease in the number of burst forming unit-erythroid colonies

immune system
• mice develop splenomegaly 10 months after tamoxifen injection
• expansion or infiltration of monocytes and granulocytes in the spleen, bone marrow, and liver of tamoxifen treated mice
• tamoxifen treated mice exhibit expansion of CD11b+Gr1+ neutrophils in spleen
• however, B-cell and T-cell numbers are normal in tamoxifen treated mice
• expansion or infiltration of monocytes and granulocytes in the spleen, bone marrow, and liver of tamoxifen treated mice

growth/size/body
• mice develop splenomegaly 10 months after tamoxifen injection

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
chronic myelomonocytic leukemia DOID:0080188 J:263565


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory